52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study
Sihoun Hahn(Mayo Clinic), Priya S. Kishnani(Duke Medical Center), Raymond Wang(Children's Hospital of Orange County), Kristina An Haack(Sanofi (France)), Yang Zhao(Sanofi (United States)), Michael J. Gambello(Emory University), David W. Stockton(Baylor College of Medicine), Susan Sparks(Children's National), Loren Peña(Cincinnati Children's Hospital Medical Center), James B. Gibson, Nancy Leslie(Cincinnati Children's Hospital Medical Center), David Kronn(New York Medical College), Richard E. Hillman(University of Missouri Health System), Pranoot Tanpaiboon(Children's National)
Cited by 0
Related Papers
Mutation of PAX9 is associated with oligodontia
|Nature Genetics|2000|528
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Reanalysis of Clinical Exome Sequencing Data
|New England Journal of Medicine|2019|303
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals
|Genetics in Medicine|2011|247